Abstract
The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cispiatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.
| Original language | English |
|---|---|
| Pages (from-to) | 23-25 |
| Number of pages | 3 |
| Journal | Journal of Chemotherapy |
| Volume | 16 |
| Issue number | SUPPL. 5 |
| Publication status | Published - Nov 2004 |
Fingerprint
Keywords
- Cisplatin
- Clinical pharmacology
- Intraperitoneal chemotherapy
ASJC Scopus subject areas
- Microbiology (medical)
- Pharmacology (medical)
Cite this
Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy. / Conti, Matteo; De Giorgi, U.; Tazzari, V.; Bezzi, F.; Baccini, C.
In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 5, 11.2004, p. 23-25.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy
AU - Conti, Matteo
AU - De Giorgi, U.
AU - Tazzari, V.
AU - Bezzi, F.
AU - Baccini, C.
PY - 2004/11
Y1 - 2004/11
N2 - The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cispiatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.
AB - The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cispiatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.
KW - Cisplatin
KW - Clinical pharmacology
KW - Intraperitoneal chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=11144239617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=11144239617&partnerID=8YFLogxK
M3 - Article
C2 - 15675471
AN - SCOPUS:11144239617
VL - 16
SP - 23
EP - 25
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
SN - 1120-009X
IS - SUPPL. 5
ER -